

Haematologica
HAEMATOL/2019/246322
Version 1

A post-stem cell transplant risk score for Ph- acute lymphoblastic
leukemia

Dietger Niederwieser

Disclosures: Dr. Niederwieser reports non-financial support from Novartis, during the conduct of the study; personal fees from Cellectis, personal fees from Daiichi, personal fees from Novartis, outside the submitted work. JCMIE summary